-

Abveris Named as One of the Best Places to Work

CANTON, Mass.--(BUSINESS WIRE)--The Business Intelligence Group today announced that it has awarded Abveris, a division of Twist Bioscience, a Best Places to Work 2022. The organization sought to identify companies that are actively working to improve their own performance through efforts to challenge employees in environments that make work fun and engaging.

“We are deeply honored to have received the Best Places to Work award for the second consecutive year,” commented Tracey Mullen, VP, General Manager of Abveris, a division of Twist Bioscience. “At the heart of our division is a diverse team of collectively driven antibody enthusiasts who are united under a shared passion for technological advancement and unbridled scientific curiosity. Our team is our greatest asset and key to our success, and this award is a testament to that.”

“Congratulations to Abveris for building a workplace focused on employee engagement and performance,” said Maria Jimenez, Chief Nominations Officer of Business Intelligence Group. “This clearly was the most challenging year for many companies, and it is clear this is a great place to work and employee feedback is not only listened to, but acted upon. Congratulations to the entire team.”

About Abveris

Abveris, a division of Twist Bioscience, provides premium in vivo antibody discovery services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global biopharma leaders. Additional information about Abveris is available at www.abveris.com.

About Business Intelligence Group

The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world. Unlike other industry and business award programs, business executives—those with experience and knowledge—judge the programs. The organization’s proprietary and unique scoring system selectively measures performance across multiple business domains and then rewards those companies whose achievements stand above those of their peers.

Contacts

Angela Bitting
Twist Bioscience
(925) 202-6211
abitting@twistbioscience.com

Maria Jimenez
Business Intelligence Group
+1 (909) 529-2737
jmaria@bintelligence.com

Abveris LogoAbveris Logo

Abveris

NASDAQ:TWST

Release Versions

Contacts

Angela Bitting
Twist Bioscience
(925) 202-6211
abitting@twistbioscience.com

Maria Jimenez
Business Intelligence Group
+1 (909) 529-2737
jmaria@bintelligence.com

More News From Abveris

Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model. TuneLab was created to accelerate biotech innovation by enabling participating compan...

Twist Bioscience to Present at Baird 2026 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in a fireside chat at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026 at 1:25 pm Eastern Time in New York City. The fireside chat will be webcast live and can be accessed by visiting the “In...

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Twist. The gross proceeds to Twist from the offering, before deducting the underwriting discounts and commissio...
Back to Newsroom